Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
AARTI DRUGS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AARTI DRUGS Mar-23 |
ADCOCK INGRAM Jun-14 |
AARTI DRUGS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 532 | 322 | - | |
Low | Rs | 311 | 232 | - | |
Sales per share (Unadj.) | Rs | 293.3 | 95.8 | - | |
Earnings per share (Unadj.) | Rs | 18.0 | -24.1 | - | |
Cash flow per share (Unadj.) | Rs | 23.4 | -20.0 | - | |
Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
Avg Dividend yield | % | 0.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 128.8 | 75.2 | - | |
Shares outstanding (eoy) | m | 92.60 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.4 | 2.9 | 49.6% | |
Avg P/E ratio | x | 23.4 | -11.5 | -204.2% | |
P/CF ratio (eoy) | x | 18.0 | -13.9 | -129.9% | |
Price / Book Value ratio | x | 3.3 | 3.7 | 88.7% | |
Dividend payout | % | 5.6 | 0 | - | |
Avg Mkt Cap | Rs m | 39,003 | 46,762 | 83.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 804 | 2,935 | 27.4% | |
Avg. sales/employee | Rs Th | 0 | 3,764.6 | - | |
Avg. wages/employee | Rs Th | 0 | 683.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -948.6 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,161 | 16,162 | 168.1% | |
Other income | Rs m | 22 | 113 | 19.4% | |
Total revenues | Rs m | 27,182 | 16,275 | 167.0% | |
Gross profit | Rs m | 3,095 | -2,801 | -110.5% | |
Depreciation | Rs m | 503 | 698 | 72.1% | |
Interest | Rs m | 371 | 438 | 84.8% | |
Profit before tax | Rs m | 2,242 | -3,823 | -58.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 578 | 239 | 242.1% | |
Profit after tax | Rs m | 1,664 | -4,072 | -40.9% | |
Gross profit margin | % | 11.4 | -17.3 | -65.7% | |
Effective tax rate | % | 25.8 | -6.2 | -412.8% | |
Net profit margin | % | 6.1 | -25.2 | -24.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,923 | 11,837 | 126.1% | |
Current liabilities | Rs m | 9,330 | 6,660 | 140.1% | |
Net working cap to sales | % | 20.6 | 32.0 | 64.3% | |
Current ratio | x | 1.6 | 1.8 | 90.0% | |
Inventory Days | Days | 6 | 111 | 5.1% | |
Debtors Days | Days | 1,162 | 124 | 937.7% | |
Net fixed assets | Rs m | 9,290 | 6,900 | 134.6% | |
Share capital | Rs m | 926 | 75 | 1,234.1% | |
Net worth | Rs m | 11,924 | 12,685 | 94.0% | |
Long term debt | Rs m | 2,047 | 4,458 | 45.9% | |
Total assets | Rs m | 24,214 | 23,963 | 101.0% | |
Interest coverage | x | 7.0 | -7.7 | -91.0% | |
Debt to equity ratio | x | 0.2 | 0.4 | 48.8% | |
Sales to assets ratio | x | 1.1 | 0.7 | 166.3% | |
Return on assets | % | 8.4 | -15.2 | -55.4% | |
Return on equity | % | 14.0 | -32.1 | -43.5% | |
Return on capital | % | 18.7 | -19.8 | -94.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,342 | 1,380 | 97.3% | |
From Investments | Rs m | -1,640 | -424 | 387.1% | |
From Financial Activity | Rs m | 165 | 4,046 | 4.1% | |
Net Cashflow | Rs m | -132 | 5,002 | -2.6% |
Compare AARTI DRUGS With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare AARTI DRUGS With: RAYMED LABS MEDICAMEN BI J.B.CHEMICALS WANBURY TRIDENT LIFELINE
Asian stocks got off to a shaky start on Thursday after the Federal Reserve flagged delays to interest rate cuts, while the dollar fell heavily on the yen in what traders reckoned was Japanese intervention.